ACM
RPTX

Aquilo Capital Management’s Repare Therapeutics RPTX Stock Holding History

Aquilo Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,293,715
Closed -$1.28M – 12
2025
Q1 		$1.28M Hold
1,293,715
– – 2.29% 12
2024
Q4 		$1.69M Buy
1,293,715
+304,351
+31% +$906K 2.56% 13
2024
Q3 		$3.4M Buy
989,364
+32,432
+3% +$107K 2.58% 13
2024
Q2 		$3.16M Buy
956,932
+323,661
+51% +$1.15M 3.04% 10
2024
Q1 		$2.98M Hold
633,271
– – 2.24% 10
2023
Q4 		$4.62M Buy
+633,271
New +$3.54M 2.88% 9

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aquilo Capital Management's RPTX Position: Q2 2025 in Review

Aquilo Capital Management sold out of Repare Therapeutics (RPTX) in Q2 2025, closing a stake of 1,293,715 shares — an estimated $1.28M sold.

Aquilo Capital Management first reported a position in RPTX in Q4 2023 and held it in 6 quarters. The position peaked at $4.62M in Q4 2023. 50 funds tracked by Wall St. Rank hold RPTX as of Q2 2025.

  • Aquilo Capital Management reported no remaining Repare Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 1,293,715 Repare Therapeutics shares in Q2 2025, an estimated $1.28M.
  • Aquilo Capital Management first reported a position in Repare Therapeutics in Q4 2023 and held it in 6 quarters.
  • Aquilo Capital Management's Repare Therapeutics position peaked at $4.62M in Q4 2023.
  • 50 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.